GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹14,925 Cr | ₹13,309 Cr | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr |
What is the latest Total Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹14,925 Cr |
| Mar2024 | ₹13,309 Cr |
| Mar2023 | ₹17,566 Cr |
| Mar2022 | ₹15,397 Cr |
| Mar2021 | ₹14,069 Cr |
How is Total Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹14,925 Cr | 12.15 | |
| Mar2024 | ₹13,309 Cr | -24.23 | |
| Mar2023 | ₹17,566 Cr | 14.08 | |
| Mar2022 | ₹15,397 Cr | 9.44 | |
| Mar2021 | ₹14,069 Cr | - | |
Compare Total Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹62,620.2 Cr | -1.9% | -2.3% | 1.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹470,270.0 Cr | -1.5% | 2.5% | 14.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹222,224.0 Cr | 7.4% | 22.2% | 26.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,325.0 Cr | 3.1% | 4.3% | 38.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.6% | -1.4% | -6.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,876.6 Cr | 1.5% | -15.2% | -9.1% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -1.9% |
-2.3% |
1.8% |
| SENSEX | 2.2% |
0.9% |
-3.7% |
You may also like the below Video Courses